2nd Quarter - Amendment

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$540,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 20, 2012 $490,457 Replaced
2nd Quarter - Amendment (this page) Dec 6, 2012 $540,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent Settlements

LobbyistCovered position, as disclosed
ELLEN JENKINS —
LARA RAMSBURG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Health Issues HCR

S. 3187 - Food and Drug Administration Safety and Innovation Act; S. 1884 - School Access to Emergency Epinephrine Act; Drug shortages; Patent settlements; Serialization; Issues related to HIV/AIDS; Funding for antiretrovirals, PEPFAR, Global Fund, FDA; Issues relating to biogenerics; Issues relating to the generic drug industry; Issues relating to Average Manufacturer Price (AMP)

LobbyistCovered position, as disclosed
ELLEN JENKINS —
BRUCE LOTT —
LARA RAMSBURG —

Contacted: SENATE; Food & Drug Administration (FDA); White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 1884 (112th), S. 3187 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.